Chronic kidney disease—mineral and bone disorders: pathogenesis and management
JB Cannata-Andía, B Martín-Carro… - Calcified tissue …, 2021 - Springer
The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …
Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future
V Brandenburg, M Ketteler - Nutrients, 2022 - mdpi.com
The association between vitamin D deficiency and especially critical shortage of active
vitamin D (1, 25-dihydroxyvitamin D, calcitriol) with the development of secondary …
vitamin D (1, 25-dihydroxyvitamin D, calcitriol) with the development of secondary …
Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial
GA Block, DA Bushinsky, S Cheng, J Cunningham… - Jama, 2017 - jamanetwork.com
Importance Secondary hyperparathyroidism contributes to extraskeletal calcification and is
associated with all-cause and cardiovascular mortality. Control is suboptimal in the majority …
associated with all-cause and cardiovascular mortality. Control is suboptimal in the majority …
An optimized machine learning framework for predicting intradialytic hypotension using indexes of chronic kidney disease-mineral and bone disorders
X Yang, D Zhao, F Yu, AA Heidari, Y Bano… - Computers in Biology …, 2022 - Elsevier
Intradialytic hypotension (IDH) is the most common acute complication in hemodialysis (HD)
sessions and is associated with increased morbidity and mortality in HD patients. To prevent …
sessions and is associated with increased morbidity and mortality in HD patients. To prevent …
[HTML][HTML] Prevention and treatment of hyperphosphatemia in chronic kidney disease
Hyperphosphatemia has consistently been shown to be associated with dismal outcome in a
wide variety of populations, particularly in chronic kidney disease (CKD). Compelling …
wide variety of populations, particularly in chronic kidney disease (CKD). Compelling …
Potential application of klotho in human chronic kidney disease
JA Neyra, MC Hu - Bone, 2017 - Elsevier
The extracellular domain of transmembrane alpha-Klotho (αKlotho, hereinafter simply called
Klotho) is cleaved by secretases and released into the circulation as soluble Klotho. Soluble …
Klotho) is cleaved by secretases and released into the circulation as soluble Klotho. Soluble …
Role of Chronic Kidney Disease (CKD)–Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD
S Yamada, T Nakano - Journal of atherosclerosis and thrombosis, 2023 - jstage.jst.go.jp
Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney
disease (CKD). Multiple factors account for the increased incidence of cardiovascular …
disease (CKD). Multiple factors account for the increased incidence of cardiovascular …
KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD …
DC Wheeler, WC Winkelmayer - Kidney international …, 2017 - discovery.ucl.ac.uk
The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline
Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease …
Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease …
[HTML][HTML] Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney …
JV Torregrosa, J Bover, MR Portillo, EG Parra… - Nefrología (English …, 2023 - Elsevier
As in 2011, when the Spanish Society of Nephrology (SEN) published the Spanish
adaptation to the Kidney Disease: Improving Global Outcomes (KDIGO) universal Guideline …
adaptation to the Kidney Disease: Improving Global Outcomes (KDIGO) universal Guideline …
Changes in bone quality after treatment with etelcalcetide
P Khairallah, J Cherasard, J Sung… - Clinical Journal of the …, 2023 - journals.lww.com
Methods In a single-arm, open-label, 36-week prospective trial, we hypothesized that
etelcalcetide improves bone quality and strength without damaging bone–tissue quality …
etelcalcetide improves bone quality and strength without damaging bone–tissue quality …